A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

RIST4721

RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

DRUG

Placebo

Matching placebo

Trial Locations (12)

23502

Virginia Clinical Research, Inc., Norfolk

33134

Florida Academic Centers Research and Education, LLC, Coral Gables

33613

ForCare Clinical Research, Tampa

35244

Cahaba Dermatology & Skin Center, Birmingham

45324

Wright State Physicians, Fairborn

46168

The Indiana Clinical Trials Center, P.C., Plainfield

78213

Progressive Clinical Research, San Antonio

85255

Investigate MD, LLC, Scottsdale

90033

USC IDS Pharmacy, Los Angeles

02215

Beth Israel Deaconess Medical Center, Boston

V3V 0C6

Enverus Medical Research, Surrey

K9A 0Z4

SKiN Health, Cobourg

Sponsors
All Listed Sponsors
lead

Aristea Therapeutics, Inc.

INDUSTRY

NCT05348681 - A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) | Biotech Hunter | Biotech Hunter